Administering ESAs to CKD patients with the goal of normalizing hemoglobin levels has not demonstrated survival or cardiovascular disease benefit, and may be harmful in comparison to a treatment regimen that delays ESA administration or sets relatively conservative targets (90–110 g/L).

Conditions: Anemia, Chronic Kidney Disease (CKD), Kidney Failure, Renal Failure

Treatments: Erythropoiesis Stimulating Agent (ESA), Erythropoietin, Epo, epoetin Alfa. Procrit, Epogen, Epoetin Beta, NeoRecormon, Darbepoetin Alfa, Aranesp, Methoxy Polyethylene Glycol-Epoetin Beta, Mircera